<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CEFUROXIME SODIUM- cefuroxime sodiumÂ injection, powder, for solutionÂ </strong><br>Samson Medical Technologies, L.L.C.<br></p></div>
<h1>Cefuroxime for Injection, USP</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="LINK_1bc99a80-58e1-4324-8fe8-2dba7c9d62d4"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">PHARMACY BULK PACKAGE - </span></p>
<p><span class="Bold">NOT FOR DIRECT INFUSION </span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_aebfa9b7-0b44-4979-a6e0-fb26d1b46109"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First">To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefuroxime and other antibacterial drugs, Cefuroxime for Injection should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria. </p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_0e563ea8-75a2-4bb7-81b3-235f668d3801"></a><a name="section-2"></a><p></p>
<h1><span class="Bold">DESCRIPTION</span></h1>
<p class="First">Cefuroxime is a semisynthetic, broad-spectrum, cephalosporin antibiotic for parenteral administration. It is the sodium salt of (6R,7R)-3-carbamoyloxymethyl-7-[Z-2-methoxyimino-2- (fur-2-yl)acetamido]ceph-3-em-4-carboxylate, and it has the following chemical structure: <img alt="This is an image of the chemical structure for Cefuroxime." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=98ea197c-b3ff-47bc-8d0f-fce91b539959&amp;name=cefuroxime-1.jpg"></p>
<p>The empirical formula is C<span class="Sub">16</span>H<span class="Sub">15</span>N<span class="Sub">4</span>NaO<span class="Sub">8</span>S, representing a molecular weight of 446.4. </p>
<p>Cefuroxime for Injection contains approximately 54.2 mg (2.4 mEq) of sodium per gram of cefuroxime activity. </p>
<p>Cefuroxime for Injection in sterile crystalline form is supplied in Pharmacy Bulk Packages equivalent to 75 g or 225 g of cefuroxime as cefuroxime sodium. Solutions of cefuroxime range in color from light yellow to amber, depending on the concentration and diluent used. The pH of freshly constituted solutions usually ranges from 6 to 8.5. </p>
<p>A Pharmacy Bulk Package is a container of a sterile preparation for intravenous use that contains many single doses. The contents are intended for use in a pharmacy admixture service and are restricted to the preparation of admixtures for intravenous infusion. <span class="Bold">BEFORE ADMINISTRATION, THIS PHARMACY BULK PACKAGE REQUIRES RECONSTITUTION TO A CONCENTRATION OF 95 mg/mL OR 100 mg/mL AND TRANSFER INTO STERILE SYRINGES. </span></p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_e60fd3da-488f-4f4b-8e2e-714f4786c558"></a><a name="section-3"></a><p></p>
<h1><span class="Bold">CLINICAL PHARMACOLOGY</span></h1>
<p class="First">Following intravenous doses of 750 mg and 1.5 g, serum concentrations were approximately 50 and 100 mcg/mL, respectively, at 15 minutes. Therapeutic serum concentrations of approximately 2 mcg/mL or more were maintained for 5.3 hours and 8 hours or more, respectively. There was no evidence of accumulation of cefuroxime in the serum following intravenous administration of 1.5-g doses every 8 hours to normal volunteers. The serum half-life after intravenous injections is approximately 80 minutes. </p>
<p>Approximately 89% of a dose of cefuroxime is excreted by the kidneys over an 8-hour period, resulting in high urinary concentrations. </p>
<p>Intravenous doses of 750 mg and 1.5 g produced urinary levels averaging 1,150 and 2,500 mcg/mL respectively during the first 8-hour period.</p>
<p>The concomitant oral administration of probenecid with cefuroxime slows tubular secretion, decreases renal clearance by approximately 40%, increases the peak serum level by approximately 30%, and increases the serum half-life by approximately 30%. Cefuroxime is detectable in therapeutic concentrations in pleural fluid, joint fluid, bile, <span class="product-label-link" type="condition" conceptid="4102774" conceptname="Productive cough">sputum</span>, bone, and aqueous humor.</p>
<p>Cefuroxime is detectable in therapeutic concentrations in cerebrospinal fluid (CSF) of adults and pediatric patients with <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>. The following table shows the concentrations of cefuroxime achieved in cerebrospinal fluid during multiple dosing of patients with <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>. </p>
<p><span class="Bold">Table 1. Concentrations of Cefuroxime Achieved in Cerebrospinal Fluid During Multiple Dosing of Patients with <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">Meningitis</span> </span></p>
<table border="1" cellpadding="7" cellspacing="0">
<col width="28%">
<col width="28%">
<col width="15%">
<col width="30%">
<tbody class="Headless">
<tr class="First">
<td align="center" valign="bottom"><p class="First">Patients </p></td>
<td align="center" valign="bottom"><p class="First">Dose </p></td>
<td align="center" valign="bottom"><p class="First">Number of Patients </p></td>
<td valign="bottom"><p class="First">Mean (Range) CSF Cefuroxime Concentrations (mcg/mL) Achieved Within 8 Hours Post Dose </p></td>
</tr>
<tr>
<td align="center"><p class="First">Pediatric patients (4 weeks to 6.5 years) </p></td>
<td><p class="First">200 mg/kg/day, divided q 6 hours </p></td>
<td align="center"><p class="First">5 </p></td>
<td><p class="First">6.6 (0.9-17.3) </p></td>
</tr>
<tr>
<td align="center"><p class="First">Pediatric patients (7 months to 9 years) </p></td>
<td><p class="First">200 to 230 mg/kg/day, divided q 8 hours </p></td>
<td align="center"><p class="First">6 </p></td>
<td><p class="First">8.3 (&lt;2-22.5) </p></td>
</tr>
<tr>
<td align="center"><p class="First">Adults </p></td>
<td><p class="First">1.5 grams q 8 hours </p></td>
<td align="center"><p class="First">2 </p></td>
<td><p class="First">5.2 (2.7-8.9) </p></td>
</tr>
<tr class="Last">
<td align="center"><p class="First">Adults </p></td>
<td><p class="First">1.5 grams q 6 hours </p></td>
<td align="center"><p class="First">10 </p></td>
<td><p class="First">6.0 (1.5-13.5) </p></td>
</tr>
</tbody>
</table>
<p>Cefuroxime is approximately 50% bound to serum protein. </p>
<p><span class="Bold">Microbiology: </span>Cefuroxime has <span class="Italics">in vitro</span> activity against a wide range of gram-positive and gram-negative organisms, and it is highly stable in the presence of beta-lactamases of certain gram-negative bacteria. The bactericidal action of cefuroxime results from inhibition of cell-wall synthesis.</p>
<p>Cefuroxime is usually active against the following organisms <span class="Italics">in vitro</span>.</p>
<p><span class="Bold"><span class="Italics">Aerobes, Gram-positive:</span></span><span class="Italics"> Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, </span>and <span class="Italics">Streptococcus pyogenes </span>(and other streptococci).</p>
<p>NOTE: Most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of enterococci, e.g., <span class="Italics">Enterococcus faecalis </span>(formerly <span class="Italics">Streptococcus faecalis</span>), are resistant to cefuroxime. Methicillin-resistant staphylococci and <span class="Italics">Listeria monocytogenes </span>are resistant to cefuroxime.</p>
<p><span class="Bold"><span class="Italics">Aerobes, Gram-negative:</span></span><span class="Italics"> Citrobacter </span>spp., <span class="Italics">Enterobacter </span>spp., <span class="Italics">Escherichia coli</span>, <span class="Italics">Haemophilus influenzae </span>(including ampicillin-resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>), <span class="Italics">Haemophilus parainfluenzae, Klebsiella </span>spp. (including <span class="Italics">Klebsiella pneumoniae</span>), <span class="Italics">Moraxella </span>(<span class="Italics">Branhamella</span>) <span class="Italics">catarrhalis </span>(including ampicillin- and cephalothin-resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>), <span class="Italics">Morganella morganii </span>(formerly <span class="Italics">Proteus morganii</span>), <span class="Italics">Neisseria gonorrhoeae </span>(including penicillinase- and non-penicillinase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>), <span class="Italics">Neisseria meningitidis, Proteus mirabilis, Providencia rettgeri </span>(formerly <span class="Italics">Proteus rettgeri</span>), <span class="Italics"><span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">Salmonella</span> </span>spp., and <span class="Italics">Shigella </span>spp.</p>
<p>NOTE: Some <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Morganella morganii, Enterobacter cloacae</span>, and <span class="Italics">Citrobacter </span>spp. have been shown by <span class="Italics">in vitro</span> tests to be resistant to cefuroxime and other cephalosporins. <span class="Italics">Pseudomonas </span>and <span class="Italics">Campylobacter </span>spp., <span class="Italics">Legionella</span> spp., <span class="Italics">Acinetobacter calcoaceticus</span>, and most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Serratia </span>spp. and <span class="Italics">Proteus vulgaris </span>are resistant to most first- and second-generation cephalosporins.</p>
<p><span class="Bold"><span class="Italics">Anaerobes: </span></span>Gram-positive and gram-negative cocci (including <span class="Italics">Peptococcus </span>and <span class="Italics">Peptostreptococcus </span>spp.), gram-positive bacilli (including <span class="Italics">Clostridium </span>spp.), and gram-negative bacilli (including <span class="Italics">Bacteroides </span>and <span class="Italics">Fusobacterium </span>spp.).</p>
<p>NOTE: <span class="Italics">Clostridium difficile </span>and most <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Bacteroides fragilis </span>are resistant to cefuroxime.</p>
<p><span class="Bold">Susceptibility Tests: <span class="Italics">Diffusion Techniques: </span></span>Quantitative methods that require measurement of zone diameters give an estimate of antibiotic susceptibility. One such standard procedure<span class="Sup">1</span> that has been recommended for use with disks to test susceptibility of organisms to cefuroxime uses the 30-mcg cefuroxime disk. Interpretation involves the correlation of the diameters obtained in the disk test with the <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentration</span> (MIC) for cefuroxime.</p>
<p>A report of â€œSusceptibleâ€? indicates that the pathogen is likely to be inhibited by generally achievable blood levels.Â  A report of "Moderately Susceptible" suggests that the organism would be susceptible if high dosage is used or if the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is confined to tissues and fluids in which high antibiotic levels are attained. A report of "Intermediate" suggests an equivocable or indeterminate result. A report of "Resistant" indicates that achievable concentrations of the antibiotic are unlikely to be inhibitory and other therapy should be selected.</p>
<p>Â Â Â Â Â  Reports from the laboratory giving results of the standard single-disk susceptibility test for organisms other than <span class="Italics">Haemophilus </span>spp. and <span class="Italics">Neisseria gonorrhoeae </span>with a 30-mcg cefuroxime disk should be interpreted according to the following criteria:</p>
<table>
<col width="200px">
<col width="200px">
<tbody class="Headless">
<tr class="First">
<td><span class="Bold"><span class="Underline">Zone Diameter (mm)</span></span></td>
<td>
<span class="Underline"><span class="Bold">Interpretation</span></span>Â </td>
</tr>
<tr>
<td>â‰¥18</td>
<td>(S) Susceptible</td>
</tr>
<tr>
<td>15-17</td>
<td>(MS) Moderately Susceptible</td>
</tr>
<tr class="Last">
<td>â‰¤14</td>
<td>(R) Resistant</td>
</tr>
</tbody>
</table>
<p>Results for <span class="Italics">Haemophilus </span>spp. should be interpreted according to the following criteria:</p>
<table>
<col width="200px">
<col width="200px">
<tbody class="Headless">
<tr class="First">
<td><span class="Bold"><span class="Underline">Zone Diameter (mm)</span></span></td>
<td>
<span class="Bold"><span class="Underline">Interpretation</span></span>Â </td>
</tr>
<tr>
<td>â‰¥24</td>
<td>(S) Susceptible</td>
</tr>
<tr>
<td>21-23</td>
<td>(I) Intermediate</td>
</tr>
<tr class="Last">
<td>â‰¤20</td>
<td>(R) Resistant</td>
</tr>
</tbody>
</table>
<p>Results for <span class="Italics">Neisseria gonorrhoeae </span>should be interpreted according to the following criteria:</p>
<table>
<col width="200px">
<col width="200px">
<tbody class="Headless">
<tr class="First">
<td><span class="Bold"><span class="Underline">Zone Diameter (mm)</span></span></td>
<td><span class="Underline"><span class="Bold">Interpretation</span>Â </span></td>
</tr>
<tr>
<td>â‰¥31</td>
<td>(S) Susceptible</td>
</tr>
<tr>
<td>26-30</td>
<td>(MS) Moderately Susceptible</td>
</tr>
<tr class="Last">
<td>â‰¤25</td>
<td>(R) Resistant</td>
</tr>
</tbody>
</table>
<p>Â Organisms should be tested with the cefuroxime disk since cefuroxime has been shown by <span class="Italics">in vitro</span> tests to be active against certain <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> found resistant when other beta-lactam disks are used.Â  The cefuroxime disk should not be used for testing susceptibility to other cephalosporins.</p>
<p>Â Â  Standardized procedures require the use of laboratory control organisms. The 30-mcg cefuroxime disk should give the following zone diameters.</p>
<p>1. Testing for organisms other than <span class="Italics">Haemophilus </span>spp. and <span class="Italics">Neisseria gonorrhoeae:</span></p>
<table>
<col width="300px">
<col width="200px">
<tbody class="Headless">
<tr class="First">
<td><span class="Bold"><span class="Underline">Organism</span></span></td>
<td><span class="Bold"><span class="Underline">Zone Diameter (mm)</span></span></td>
</tr>
<tr>
<td>
<span class="Italics">Staphylococcus aureus </span>ATCC 25923</td>
<td>27-35</td>
</tr>
<tr class="Last">
<td>
<span class="Italics">Escherichia coli </span>ATCC 25922</td>
<td>20-26</td>
</tr>
</tbody>
</table>
<p>2. Testing for <span class="Italics">Haemophilus </span>spp.:</p>
<table>
<col width="300px">
<col width="200px">
<tbody class="Headless">
<tr class="First">
<td><span class="Bold"><span class="Underline">Organism</span></span></td>
<td><span class="Bold"><span class="Underline">Zone Diameter (mm)</span></span></td>
</tr>
<tr class="Last">
<td>
<span class="Italics">Haemophilus influenzae </span>ATCC 49766</td>
<td>28-36</td>
</tr>
</tbody>
</table>
<p>3. Testing for <span class="Italics">Neisseria gonorrhoeae</span></p>
<table>
<col width="300px">
<col width="200px">
<tbody class="Headless">
<tr class="First">
<td><span class="Bold"><span class="Underline">Organism</span></span></td>
<td><span class="Bold"><span class="Underline">Zone Diameter (mm)</span></span></td>
</tr>
<tr>
<td>
<span class="Italics">Neisseria gonorrhoeae </span>ATCC 49226</td>
<td>33-41</td>
</tr>
<tr class="Last">
<td>
<span class="Italics">Staphylococcus aureus </span>ATCC 25923</td>
<td>29-33</td>
</tr>
</tbody>
</table>
<p><span class="Bold"><span class="Italics">Dilution Techniques: </span></span>Use a standardized dilution method<span class="Sup">1</span> (broth, agar, microdilution) or equivalent with cefuroxime powder. The MIC values obtained for bacterial isolates other than <span class="Italics">Haemophilus </span>spp. and <span class="Italics">Neisseria gonorrhoeae </span>should be interpreted according to the following criteria:</p>
<table>
<col width="150px">
<col width="200px">
<tbody class="Headless">
<tr class="First">
<td><span class="Bold"><span class="Underline">MIC (mcg/mL)Â </span></span></td>
<td><span class="Bold"><span class="Underline">Interpretation</span></span></td>
</tr>
<tr>
<td>â‰¤8</td>
<td>(S) Susceptible</td>
</tr>
<tr>
<td>16</td>
<td>(MS) Moderately Susceptible</td>
</tr>
<tr class="Last">
<td>â‰¥32</td>
<td>(R) Resistant</td>
</tr>
</tbody>
</table>
<p>MIC values obtained for <span class="Italics">Haemophilus </span>spp. should be interpreted according to the following criteria:</p>
<table>
<col width="150px">
<col width="200px">
<tbody class="Headless">
<tr class="First">
<td><span class="Bold"><span class="Underline">MIC (mcg/mL)Â </span></span></td>
<td><span class="Bold"><span class="Underline">Interpretation</span></span></td>
</tr>
<tr>
<td>â‰¤4</td>
<td>(S) Susceptible</td>
</tr>
<tr>
<td>8</td>
<td>(I) Intermediate</td>
</tr>
<tr class="Last">
<td>â‰¥16</td>
<td>(R) Resistant</td>
</tr>
</tbody>
</table>
<p>MIC values obtained for <span class="Italics">Neisseria gonorrhoeae </span>should be interpreted according to the following criteria:</p>
<table>
<col width="150px">
<col width="200px">
<tbody class="Headless">
<tr class="First">
<td><span class="Underline"><span class="Bold">MIC (mcg/mL)Â </span></span></td>
<td><span class="Underline"><span class="Bold">Interpretation</span></span></td>
</tr>
<tr>
<td>â‰¤1</td>
<td>(S) Susceptible</td>
</tr>
<tr>
<td>2</td>
<td>(MS) Moderately Susceptible</td>
</tr>
<tr class="Last">
<td>â‰¥4</td>
<td>(R) Resistant</td>
</tr>
</tbody>
</table>
<p>Â Â  As with standard diffusion techniques, dilution methods require the use of laboratory control organisms. Standard cefuroxime powder should provide the following MIC values.</p>
<p>1. For organisms other than <span class="Italics">Haemophilus </span>spp. and <span class="Italics">Neisseria gonorrhoeae</span>:</p>
<table>
<col width="300px">
<col width="200px">
<tbody class="Headless">
<tr class="First">
<td><span class="Bold"><span class="Underline">Organism</span></span></td>
<td><span class="Bold"><span class="Underline">MIC (mcg/mL)</span></span></td>
</tr>
<tr>
<td>
<span class="Italics">Staphylococcus aureus </span>ATCC 29213</td>
<td>0.5-2</td>
</tr>
<tr class="Last">
<td>
<span class="Italics">Escherichia coli </span>ATCC 25922</td>
<td>2-8</td>
</tr>
</tbody>
</table>
<p>2. For <span class="Italics">Haemophilus </span>spp.:</p>
<table>
<col width="300px">
<col width="200px">
<tbody class="Headless">
<tr class="First">
<td><span class="Bold"><span class="Underline">Organism</span></span></td>
<td><span class="Bold"><span class="Underline">MIC (mcg/mL)</span></span></td>
</tr>
<tr class="Last">
<td>
<span class="Italics">Haemophilus influenzae </span>ATCC 49766</td>
<td>0.25-1</td>
</tr>
</tbody>
</table>
<p>3. For <span class="Italics">Neisseria gonorrhoeae</span>:</p>
<table>
<col width="300px">
<col width="200px">
<tbody class="Headless">
<tr class="First">
<td><span class="Bold"><span class="Underline">Organism</span></span></td>
<td><span class="Bold"><span class="Underline">MIC (mcg/mL)</span></span></td>
</tr>
<tr>
<td>
<span class="Italics">Neisseria gonorrhoeae </span>ATCC 49226</td>
<td>0.25-1</td>
</tr>
<tr class="Last">
<td>
<span class="Italics">Staphylococcus aureus </span>ATCC 29213</td>
<td>0.25-1</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_b7c3a853-6b1c-44f9-8d11-15f14caf85c1"></a><a name="section-4"></a><p></p>
<h1><span class="Bold">INDICATIONS AND USAGE</span></h1>
<p class="First">Cefuroxime for Injection is indicated for the treatment of patients with <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the designated organisms in the following diseases:</p>
<p><span class="Bold">1. <span class="product-label-link" type="condition" conceptid="4175297" conceptname="Lower respiratory tract infection">Lower Respiratory Tract Infections</span>, </span>including <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, caused by <span class="Italics">Streptococcus pneumoniae</span>, <span class="Italics">Haemophilus influenzae </span>(including ampicillin-resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>), <span class="Italics">Klebsiella </span>spp., <span class="Italics">Staphylococcus aureus </span>(penicillinase- and non-penicillinase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>), <span class="Italics">Streptococcus pyogenes</span>, and <span class="Italics">Escherichia coli</span>.</p>
<p><span class="Bold">2. <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary Tract Infections</span> </span>caused by <span class="Italics">Escherichia coli </span>and <span class="Italics">Klebsiella </span>spp.</p>
<p><span class="Bold">3. Skin and Skin-Structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> </span>caused by <span class="Italics">Staphylococcus aureus </span>(penicillinase- and non-penicillinase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>), <span class="Italics">Streptococcus pyogenes</span>, <span class="Italics">Escherichia coli</span>, <span class="Italics">Klebsiella </span>spp., and <span class="Italics">Enterobacter </span>spp.</p>
<p><span class="Bold">4. <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">Septicemia</span> </span>caused by <span class="Italics">Staphylococcus aureus </span>(penicillinase- and non-penicillinase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>), <span class="Italics">Streptococcus pneumoniae</span>, <span class="Italics">Escherichia coli</span>, <span class="Italics">Haemophilus influenzae </span>(including ampicillin-resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>), and <span class="Italics">Klebsiella </span>spp. </p>
<p><span class="Bold">5. <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">Meningitis</span> </span>caused by <span class="Italics">Streptococcus pneumoniae</span>, <span class="Italics">Haemophilus influenzae </span>(including ampicillin-resistant <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>), <span class="Italics">Neisseria meningitidis</span>, and <span class="Italics">Staphylococcus aureus </span>(penicillinase- and non-penicillinase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>).</p>
<p><span class="Bold">6. <span class="product-label-link" type="condition" conceptid="433417" conceptname="Gonorrhea">Gonorrhea</span>: </span>Uncomplicated and disseminated gonococcal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to <span class="Italics">Neisseria gonorrhoeae </span>(penicillinase- and non-penicillinase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>) in both males and females.</p>
<p><span class="Bold">7. Bone and <span class="product-label-link" type="condition" conceptid="4180167" conceptname="Infectious disorder of joint">Joint Infections</span> </span>caused by <span class="Italics">Staphylococcus aureus </span>(penicillinase- and non- penicillinase-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>).</p>
<p>Â Â  Clinical microbiological studies in skin and skin-structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> frequently reveal the growth of susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of both aerobic and anaerobic organisms. Cefuroxime for Injection has been used successfully in these mixed <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in which several organisms have been isolated.Â  </p>
<p>Â Â  In certain cases of confirmed or suspected gram-positive or gram-negative <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> or in patients with other serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> in which the causative organism has not been identified, Cefuroxime for Injection may be used concomitantly with an aminoglycoside (see <a href="#LINK_6fcdd9a4-fd1f-4cc9-b39d-e07d38f3515d">PRECAUTIONS</a>). The recommended doses of both antibiotics may be given depending on the severity of the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> and the patientâ€™s condition. </p>
<p>Â Â  To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefuroxime for Injection and other antibacterial drugs, Cefuroxime for Injection should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.Â  In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
<p><span class="Bold">Prevention: </span>The preoperative <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> administration of cefuroxime may prevent the growth of susceptible disease-causing bacteria and thereby may reduce the incidence of certain <span class="product-label-link" type="condition" conceptid="437474" conceptname="Postoperative infection">postoperative infections</span> in patients undergoing surgical procedures (e.g., vaginal hysterectomy) that are classified as clean-contaminated or potentially contaminated procedures. Effective <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> use of antibiotics in surgery depends on the time of administration.Â  Cefuroxime should usually be given one-half to 1 hour before the operation to allow sufficient time to achieve effective antibiotic concentrations in the <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> tissues during the procedure. The dose should be repeated intraoperatively if the surgical procedure is lengthy.</p>
<p>Â Â  <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">Prophylactic</span> administration is usually not required after the surgical procedure ends and should be stopped within 24 hours. In the majority of surgical procedures, continuing <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> administration of any antibiotic does not reduce the incidence of subsequent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> but will increase the possibility of adverse reactions and the development of <span class="product-label-link" type="condition" conceptid="4207042" conceptname="Viral resistance">bacterial resistance</span>. </p>
<p>Â Â  The perioperative use of cefuroxime has also been effective during open-heart surgery for surgical patients in whom <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> at the operative site would present a serious risk. For these patients it is recommended that therapy with cefuroxime be continued for at least 48 hours after the surgical procedure ends. If an <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is present, specimens for culture should be obtained for the identification of the causative organism, and appropriate antimicrobial therapy should be instituted.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_f78e6910-863b-4192-93c1-61b51c9fce9f"></a><a name="section-5"></a><p></p>
<h1><span class="Bold">CONTRAINDICATIONS</span></h1>
<p class="First">Â Â  Cefuroxime for Injection is contraindicated in patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> to the cephalosporin group of antibiotics.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_1f8708a7-8bc0-4f56-b73b-894942f21894"></a><a name="section-6"></a><p></p>
<h1><span class="Bold">WARNINGS</span></h1>
<p class="First">BEFORE THERAPY WITH CEFUROXIME FOR INJECTION IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span> TO CEPHALOSPORINS, PENICILLINS, OR OTHER DRUGS. THIS PRODUCT SHOULD BE GIVEN CAUTIOUSLY TO PENICILLIN-SENSITIVE PATIENTS. ANTIBIOTICS SHOULD BE ADMINISTERED WITH CAUTION TO ANY PATIENT WHO HAS DEMONSTRATED SOME FORM OF <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">ALLERGY</span>, PARTICULARLYÂ  TO DRUGS. IF AN <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">ALLERGIC REACTION</span> TO CEFUROXIME OCCURS, DISCONTINUE THE DRUG.Â  SERIOUS ACUTE <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY REACTIONS</span> MAY REQUIRE EPINEPHRINE AND OTHER EMERGENCY MEASURES.</p>
<p><span class="Italics">Clostridium difficile</span> associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents, including cefuroxime, and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <span class="Italics">C. difficile</span>.</p>
<p>Â Â  <span class="Italics">C. difficile</span> produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">C. difficile</span> cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.</p>
<p>Â Â  If CDAD is suspected or confirmed, ongoing antibiotic use not directed against <span class="Italics">C. difficile</span> may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of <span class="Italics">C. difficile</span>, and surgical evaluation should be instituted as clinically indicated.Â  </p>
<p>Â Â  When the <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> is not relieved by drug discontinuation or when it is severe, oral vancomycin is the treatment of choice for antibiotic-associated <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> produced by <span class="Italics">Clostridium difficile</span>. Other causes of <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span> should also be considered.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="LINK_6fcdd9a4-fd1f-4cc9-b39d-e07d38f3515d"></a><a name="section-7"></a><p></p>
<h1><span class="Bold">PRECAUTIONS</span></h1>
<div class="Section" data-sectionCode="34072-9">
<a name="LINK_c7e4be09-3669-4704-a937-8c7dec7a2d91"></a><a name="section-7.1"></a><p></p>
<h2><span class="Bold">General:</span></h2>
<p class="First"><span class="Bold">Â </span>Although cefuroxime rarely produces alterations in kidney function, evaluation of renal status during therapy is recommended, especially in seriously ill patients receiving the maximum doses. Cephalosporins should be given with caution to patients receiving concurrent treatment with potent diuretics as these regimens are suspected of adversely affecting renal function.</p>
<p>Â Â  The total daily dose of cefuroxime should be reduced in patients with transient or persistent <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> (see <a href="#LINK_c6b38576-8a4d-4f59-a399-8a228e23ebc6">DOSAGE AND ADMINISTRATION</a>), because high and prolonged serum antibiotic concentrations can occur in such individuals from usual doses.</p>
<p>Â Â  As with other antibiotics, prolonged use of cefuroxime may result in overgrowth of nonsusceptible organisms. Careful observation of the patient is essential. If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> occurs during therapy, appropriate measures should be taken.</p>
<p>Â Â  Broad-spectrum antibiotics should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>.</p>
<p>Â Â  <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">Nephrotoxicity</span> has been reported following concomitant administration of aminoglycoside antibiotics and cephalosporins.</p>
<p>Â Â  As with other therapeutic regimens used in the treatment of <span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span>, mild-to-moderate <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span> has been reported in a few pediatric patients treated with cefuroxime. Persistence of positive CSF (cerebrospinal fluid) cultures at 18 to 36 hours has also been noted with cefuroxime injection, as well as with other antibiotic therapies; however, the clinical relevance of this is unknown.</p>
<p>Â Â Â  Cephalosporins may be associated with a <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> in <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> activity. Those at risk include patients with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, or poor nutritional state, as well as patients receiving a protracted course of antimicrobial therapy, and patients previously stabilized on anticoagulant therapy. <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">Prothrombin</span> time should be monitored in patients at risk and exogenous Vitamin K administered as indicated.</p>
<p>Â Â  Prescribing Cefuroxime for Injection in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_81d6984d-4faa-4dd6-87e0-486a4fc633ab"></a><a name="section-7.2"></a><p></p>
<h2><span class="Bold">Information for Patients:</span></h2>
<p class="First">Patients should be counseled that antibacterial drugs, including Cefuroxime for Injection, should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When Cefuroxime for Injection is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may: (1) decrease the effectiveness of the immediate treatment, and (2)Â  increase the likelihood that bacteria will develop resistance and will not be treatable by cefuroxime or other antibacterial drugs in the future.</p>
<p>Â Â  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as 2 or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="LINK_17a27532-8918-4dc6-988f-62f4ebbb987f"></a><a name="section-7.3"></a><p></p>
<h2><span class="Bold">Drug Interactions:</span></h2>
<p class="First">In common with other antibiotics, cefuroxime may affect the gut flora, leading to lower estrogen reabsorption and reduced efficacy of combined estrogen/progesterone oral contraceptives.</p>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="LINK_01b5d66e-5fc5-46ce-9b2b-0845471f9877"></a><a name="section-7.4"></a><p></p>
<h2><span class="Bold">Drug/Laboratory Test Interactions:</span></h2>
<p class="First">A false-positive reaction for glucose in the urine may occur with copper reduction tests (Benedictâ€™s or Fehlingâ€™s solution or with CLINITESTÂ® tablets) but not with enzyme-based tests for <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span>. As a false-negative result may occur in the ferricyanide test; it is recommended that either the glucose oxidase or hexokinase method be used to determine blood plasma glucose levels in patients receiving cefuroxime.</p>
<p>Â Â  Cefuroxime does not interfere with the assay of serum and urine creatinine by the alkaline picrate method.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_c99a0a10-4bd7-435e-b649-4050037e4fe5"></a><a name="section-7.5"></a><p></p>
<h2><span class="Bold">Carcinogenesis, Mutagenesis, Impairment of Fertility:</span></h2>
<p class="First">Although lifetime studies in animals have not been performed to evaluate carcinogenic potential, no mutagenic activity was found for cefuroxime in the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay and a battery of bacterial mutation tests. Positive results were obtained in an <span class="Italics">in vitro</span> chromosome aberration assay; however, negative results were found in an <span class="Italics">in vivo</span> micronucleus test at doses up to 10 g/kg. Reproduction studies in mice at doses up to 3,200 mg/kg/day (3.1 times the recommended maximum human dose based on mg/m<span class="Sup">2</span>) have revealed no impairment of fertility.</p>
<p>Â  Reproductive studies revealed no impairment of fertility in animals.</p>
</div>
<div class="Section" data-sectionCode="34077-8">
<a name="LINK_c2b5c0a9-bcb8-45e1-b946-4612fc4d4460"></a><a name="section-7.6"></a><p></p>
<h2><span class="Bold">Pregnancy: <span class="Italics">Teratogenic Effects:</span></span></h2>
<p class="First">Pregnancy Category B. Reproduction studies have been performed in mice at doses up to 6,400 mg/kg/day (6.3 times the recommended maximum human dose based on mg/m<span class="Sup">2</span>) and rabbits at doses up to 400 mg/kg/day (2.1 times the recommended maximum human dose based on mg/m<span class="Sup">2</span>) and have revealed no evidence of impaired fertility or harm to the fetus due to cefuroxime. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_3cde60b3-cd2c-46cc-8163-7869a07b748f"></a><a name="section-7.7"></a><p></p>
<h2>
<span class="Bold">Nursing Mothers</span>:</h2>
<p class="First">Since cefuroximeis excreted in human milk, caution should be exercised when cefuroxime is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_6f9a1375-2743-41cf-b8d5-a7a51c734af8"></a><a name="section-7.8"></a><p></p>
<h2><span class="Bold">Pediatric Use:</span></h2>
<p class="First">Safety and effectiveness in pediatric patients below 3 months of age have not been established. Accumulation of other members of the cephalosporin class in newborn infants (with resulting prolongation of drug half-life) has been reported.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="LINK_4bcb7cf7-d87b-452f-a2ef-5fa4a2dc98fc"></a><a name="section-7.9"></a><p></p>
<h2><span class="Bold">Geriatric Use:</span></h2>
<p class="First">Of the 1,914 subjects who received cefuroxime in 24 clinical studies of cefuroxime, 901 (47%) were 65 and over while 421 (22%) were 75 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater susceptibility of some older individuals to drug effects cannot be ruled out. This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function (see<a href="#LINK_c6b38576-8a4d-4f59-a399-8a228e23ebc6"> DOSAGE AND ADMINISTRATION</a>).</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_6fe9071f-b806-4a91-8d04-78c16f115dd3"></a><a name="section-8"></a><p></p>
<h1><span class="Bold">ADVERSE REACTIONS</span></h1>
<p class="First">Cefuroxime is generally well tolerated. The most common adverse effects have been local reactions following intravenous administration. Other adverse reactions have been encountered only rarely.</p>
<p><span class="Bold">Local Reactions: </span><span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">Thrombophlebitis</span> has occurred with intravenous administration in 1 in 60 patients.</p>
<p><span class="Bold">Gastrointestinal: </span><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal symptoms</span> occurred in 1 in 150 patients and included <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (1 in 220 patients) and <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (1 in 440 patients). The onset of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> may occur during or after antibacterial treatment (see <a href="#LINK_1f8708a7-8bc0-4f56-b73b-894942f21894">WARNINGS</a>).</p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span>: </span><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> have been reported in fewer than 1% of the patients treated with cefuroxime and include <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> (1 in 125). <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, and positive Coombsâ€™ test each occurred in fewer than 1 in 250 patients, and, as with other cephalosporins, rare cases of <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">drug fever</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, and <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span> have occurred.</p>
<p><span class="Bold">Blood: </span>A decrease in hemoglobin and hematocrit has been observed in 1 in 10 patients and transient <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span> in 1 in 14 patients. Less common reactions seen were transient <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span> (fewer than 1 in 100 patients) and <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span> (1 in 750 patients). A similar pattern and incidence were seen with other cephalosporins used in controlled studies. As with other cephalosporins, there have been rare reports of <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.</p>
<p><span class="Bold">Hepatic: </span>Transient rise in <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> and SGPT (1 in 25 patients), alkaline phosphatase (1 in 50 patients), LDH (1 in 75 patients), and bilirubin (1 in 500 patients) levels has been noted.</p>
<p><span class="Bold">Kidney: </span>Elevations in serum creatinine and/or blood urea nitrogen and a decreased creatinine clearance have been observed, but their relationship to cefuroxime is unknown.</p>
<p><span class="Bold">Postmarketing Experience with Cefuroxime for Injection Products: </span>In addition to the adverse events reported during clinical trials, the following events have been observed during clinical practice in patients treated with cefuroxime and were reported spontaneously. Data are generally insufficient to allow an estimate of incidence or to establish causation.</p>
<p><span class="Bold"><span class="Italics">Â Â  <span class="product-label-link" type="condition" conceptid="440371" conceptname="Disorder of immune function">Immune System Disorders</span></span></span>: <span class="product-label-link" type="condition" conceptid="4182711" conceptname="Vasculitis of the skin">Cutaneous vasculitis</span><span class="Bold"><span class="Italics">Â  </span></span></p>
<p><span class="Bold"><span class="Italics">Â Â  Neurologic: </span></span><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span>.</p>
<p><span class="Bold"><span class="Italics">Â Â  Non-site specific: </span></span><span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">Angioedema</span>.</p>
<p><span class="Bold">Cephalosporin-class Adverse Reactions: </span>In addition to the adverse reactions listed above that have been observed in patients treated with cefuroxime, the following adverse reactions and altered laboratory tests have been reported for cephalosporin-class antibiotics:</p>
<p><span class="Bold"><span class="Italics">Â Â  Adverse Reactions: </span></span><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>, <span class="product-label-link" type="condition" conceptid="4081648" conceptname="Acute vaginitis">vaginitis</span> including <span class="product-label-link" type="condition" conceptid="198363" conceptname="Candidiasis of vagina">vaginal candidiasis</span>, <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">toxic nephropathy</span>, hepatic dysfunction including <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>.</p>
<p>Â Â  Several cephalosporins, including cefuroxime, have been implicated in triggering <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, particularly in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> when the dosage was not reduced (see <a href="#LINK_c6b38576-8a4d-4f59-a399-8a228e23ebc6">DOSAGE AND ADMINISTRATION</a>). If <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> associated with drug therapy should occur, the drug should be discontinued. Anticonvulsant therapy can be given if clinically indicated.</p>
<p><span class="Bold"><span class="Italics">Â Â  Altered Laboratory Tests: </span></span>Prolonged <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> time, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_738cab51-d1d4-4967-8806-8ec0fa533fc6"></a><a name="section-9"></a><p></p>
<h1><span class="Bold">OVERDOSAGE</span></h1>
<p class="First">Overdosage of cephalosporins can cause cerebral irritation leading to <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>. Serum levels of cefuroxime can be reduced by hemodialysis and peritoneal dialysis.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_c6b38576-8a4d-4f59-a399-8a228e23ebc6"></a><a name="section-10"></a><p></p>
<h1><span class="Italics"><span class="Bold">DOSAGE AND ADMINISTRATION</span></span></h1>
<p class="First"><span class="Bold">THIS IS A PHARMACY BULK PACKAGE â€“ NOT FOR DIRECT INJECTION.</span></p>
<p><span class="Bold">BEFORE ADMINISTRATION, THIS PHARMACY BULK PACKAGE REQUIRES RECONSTITUTION TO A CONCENTRATION OF 95 mg/mL OR 100 mg/mL AND TRANSFER INTO STERILE SYRINGES.</span></p>
<p><span class="Bold">Dosage: </span><span class="Bold"><span class="Italics">Adults: </span></span>The usual adult dosage range for Cefuroxime for Injection is 750 mg to 1.5 grams every 8 hours, usually for 5 to 10 days. In uncomplicated <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span>, skin and skin-structure <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, disseminated gonococcal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, and uncomplicated <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, a 750-mg dose every 8 hours is recommended. In severe or complicated <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, a 1.5-gram dose every 8 hours is recommended.</p>
<p>Â Â  In bone and <span class="product-label-link" type="condition" conceptid="4180167" conceptname="Infectious disorder of joint">joint infections</span>, a 1.5-gram dose every 8 hours is recommended. In clinical trials, <span class="product-label-link" type="condition" conceptid="4121697" conceptname="Surgery">surgical intervention</span> was performed when indicated as an adjunct to therapy with cefuroxime.Â  A course of oral antibiotics was administered when appropriate following the completion of parenteral administration of cefuroxime.</p>
<p>Â Â  In life-threatening <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> or <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to less susceptible organisms, 1.5 grams every 6 hours may be required. In <span class="product-label-link" type="condition" conceptid="436091" conceptname="Bacterial meningitis">bacterial meningitis</span>, the dosage should not exceed 3 grams every 8 hours.Â  For preventive use for clean-contaminated or potentially contaminated surgical procedures, a 1.5-gram dose administered intravenously just before surgery (approximately one-half to 1 hour before the initial incision) is recommended. Thereafter, give 750 mg intravenously every 8 hours when the procedure is prolonged.</p>
<p>Â Â  For preventive use during open-heart surgery, a 1.5-gram dose administered intravenously at the induction of anesthesia and every 12 hours thereafter for a total of 6 grams is recommended.</p>
<p><span class="Bold"><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Impaired Renal Function</span></span></span><span class="Bold"><span class="Italics">: </span></span>A reduced dosage must be employed when renal function is impaired. Dosage should be determined by the degree of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and the susceptibility of the causative organism (see Table 2). </p>
<p><span class="Bold">Table 2. Dosage of Cefuroxime For Injection in Adults With Reduced Renal Function</span></p>
<table border="1" cellpadding="0" cellspacing="0">
<col width="86.1pt">
<col width="86.1pt">
<col width="86.1pt">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Creatinine Clearance(mL/min)</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Dose</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">Frequency</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">&gt;20</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">750 mg-1.5 grams</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">q8h</p></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">10-20</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">750 mg</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">q12h</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">&lt;10</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">750 mg</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center"><p class="First">q24h*</p></td>
</tr>
</tbody>
</table>
<p>Â­Â­Â­Â­Â­Â­Â­Â­Â­Â­Â­Â­Â­Â­Â­Â­Â­Â­Â­Â­Â­Â­Â­Â­Â­Â­Â­Â­*Since cefuroxime is dialyzable, patients on hemodialysis should be given a further dose at the end of the dialysis.</p>
<p>Â Â  When only serum creatinine is available, the following formula<span class="Sup">2</span> (based on sex, weight, and age of the patient) may be used to convert this value into creatinine clearance. The serum creatinine should represent a steady state of renal function.</p>
<p>Males: Creatinine clearance (mL/min) = <span class="Underline">Weight (kg) x (140 - age)<br></span>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  Â Â Â Â Â Â Â Â Â Â Â Â  72 x serum creatinine (mg/dL) </p>
<p>Females: 0.85 x male value</p>
<p><span class="Bold">Note: </span>As with antibiotic therapy in general, administration of cefuroxime should be continued for a minimum of 48 to 72 hours after the patient becomes asymptomatic or after evidence of bacterial eradication has been obtained; a minimum of 10 days of treatment is recommended in <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> caused by <span class="Italics">Streptococcus pyogenes </span>in order to guard against the risk of <span class="product-label-link" type="condition" conceptid="442313" conceptname="Rheumatic fever">rheumatic fever</span> or <span class="product-label-link" type="condition" conceptid="4263367" conceptname="Glomerulonephritis">glomerulonephritis</span>; frequent bacteriologic and clinical appraisal is necessary during therapy of chronic <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infection</span> and may be required for several months after therapy has been completed; persistent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> may require treatment for several weeks; and doses smaller than those indicated above should not be used. In staphylococcal and other <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> involving a collection of pus, surgical drainage should be carried out where indicated.</p>
<p><span class="Bold"><span class="Italics">Â Â  </span></span></p>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_680d0363-0ee8-4b09-afd8-7de1fb9473a9"></a><a name="section-10.1"></a><p></p>
<h2><span class="Italics"><span class="Bold">Pediatric Patients Above 3 Months of Age:</span></span></h2>
<p class="First">Administration of 50 to 100 mg/kg/day in equally divided doses every 6 to 8 hours has been successful for most <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> susceptible to cefuroxime. The higher dosage of 100 mg/kg/day (not to exceed the maximum adult dosage) should be used for the more severe or serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>. </p>
<p>Â Â  In bone and <span class="product-label-link" type="condition" conceptid="4180167" conceptname="Infectious disorder of joint">joint infections</span>, 150 mg/kg/day (not to exceed the maximum adult dosage) is recommended in equally divided doses every 8 hours. In clinical trials, a course of oral antibiotics was administered to pediatric patients following the completion of parenteral administration of cefuroxime.</p>
<p>Â Â  In cases of <span class="product-label-link" type="condition" conceptid="436091" conceptname="Bacterial meningitis">bacterial meningitis</span>, a larger dosage of Cefuroxime for Injection is recommended, 200 to 240 mg/kg/day intravenously in divided doses every 6 to 8 hours.</p>
<p>Â Â  In pediatric patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>, the frequency of dosing should be modified consistent with the recommendations for adults.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_d601ee07-e4ce-47c6-8028-716057178669"></a><a name="section-10.2"></a><p></p>
<h2><span class="Bold">Preparation of Solution:</span></h2>
<p class="First">The directions for preparing cefuroxime for intravenous use are summarized in Table 3.Â  </p>
<p>AFTER INITIAL ENTRY USE ENTIRE CONTENTS OF THE PHARMACY BULK PACKAGE PROMPTLY; ANY UNUSED PORTION MUST BE DISCARDED WITHIN <span class="Bold">4 HOURS</span>.</p>
<p>As with other cephalosporins, cefuroxime powder as well as solutions tend to darken, depending on storage conditions, without adversely affecting potency.</p>
<p>Note: Prior to administration, parenteral drug products should be inspected visually for particulate matter and discoloration whenever solution and container permit.Â  If particulate matter is evident in reconstituted fluids the drug solutions should be discarded.</p>
<p><span class="Bold">Table 3. Preparation of Solution For Intravenous Use Only</span></p>
<table>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom">Strength</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Amount of<br>Sterile Water to<br>Be Added<br>(mL)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="bottom"><p class="First">Volume to Be<br>Withdrawn</p></td>
<td class="Botrule Lrule Rrule Toprule" align="center">Approximate<br>Concentration<br>Cefuroxime<br>(mg/mL)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2">75-gram Pharmacy Bulk Package</td>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2">770</td>
<td align="center"><p class="First">8 mL = 750 mg*</p></td>
<td class="Lrule Rrule" align="center">95</td>
</tr>
<tr>
<td class="Botrule" align="center">16 mL = 1.5 grams*</td>
<td class="Botrule Lrule Rrule" align="center">95</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2">Â </td>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2">720</td>
<td align="center">7.5 mL = 750 mg*</td>
<td class="Lrule Rrule" align="center">100</td>
</tr>
<tr>
<td class="Botrule" align="center">15 mL = 1.5 grams*</td>
<td class="Botrule Lrule Rrule" align="center">100</td>
</tr>
<tr><td class="Lrule Rrule" align="center" colspan="4">Â </td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2">225-gram Pharmacy Bulk Package</td>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2">2310</td>
<td class="Toprule" align="center">8 mL = 750 mg*</td>
<td class="Lrule Rrule Toprule" align="center">95</td>
</tr>
<tr>
<td class="Botrule" align="center">16 mL = 1.5 grams*</td>
<td class="Botrule Lrule Rrule" align="center">95</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2">Â </td>
<td class="Botrule Lrule Rrule Toprule" align="center" rowspan="2">2160</td>
<td align="center">Â 7.5 mL = 750 mg*</td>
<td class="Lrule Rrule" align="center">100</td>
</tr>
<tr class="Last">
<td class="Botrule" align="center">15 mL = 1.5 grams*</td>
<td class="Botrule Lrule Rrule" align="center">100</td>
</tr>
</tbody>
</table>
<p>*Cefuroxime as Cefuroxime Sodium.</p>
<p><span class="Bold">Directions for Proper Use of a Pharmacy Bulk Package</span></p>
<p>Not for direct infusion. The Pharmacy Bulk Package is for use in the hospital pharmacy admixture service only in a suitable work area, such as a laminar flow hood.Â Using aseptic technique, the container closure may be penetrated only one time using a new suitable sterile dispensing set or transfer device that allows measured dispensing of the contents. Use of a syringe and needle is not recommended as it may cause leakage.Â The withdrawal of container contents should be accomplished without delay.Â However, should this not be possible, a maximum time of <span class="Bold">4 HOURS</span> from initial port closure entries is permitted to complete fluid transfer operations.Â This time limit should begin with the introduction of the solvent or diluent into the Pharmacy Bulk Pack. </p>
<p><span class="Bold">Instructions for Reconstitution</span>:Â  Visually examine outer (natural foil) bag for damage.Â  IF THE SEAL IS BROKEN OR DAMAGE IS OBSERVED, DO NOT OPEN THE OUTER BAG.Â  <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">STERILITY</span> OF THE INNER BAG SURFACE MAY BE COMPROMISED.Â  DISCARD BOTH BAGS IMMEDIATELY.Â  Using aseptic technique, open outer bag at tear notch.Â  Remove, unfold and lay inner bag flat in a laminar flow hood.Â  <span class="Bold">DO NOT USE THE INNER BAG IF PARTICULATE OR FOREIGN MATTER IS PRESENT, IF THE DRY POWDER IS DARK YELLOW OR BROWN, IF THE SEALS ARE NOT INTACT, OR IF THERE IS ANY OTHER DAMAGE TO THE BAG.Â  IN SUCH CASES, DISCARD THE BAG IMMEDIATELY.</span>Â  Remove the translucent unthreaded cap from the reconstitution (smaller) port and discard it.Â  Follow the above <span class="Bold">â€œDirections for Proper Use of a Pharmacy Bulk Packageâ€?</span> and proceed to reconstitute the powder through the reconstitution (smaller) port, using Sterile Water for Injection.Â  Mix gently by picking up the bag and gently moving from side to side or by recirculating via a tubing loop until dissolution is complete. Once the powder is completely dissolved, approximately <span class="Bold">15</span> minutes for 75 grams or <span class="Bold">25</span> minutes for 225 grams, hang the bag from the eyelets support.Â  </p>
<p>If a pump is used, the following general procedure is recommended:</p>
<p>1.Â Â Â Â Â Â Â Â  For the reconstitution procedure, assemble a sterile transfer tubing set, an individually packaged sterile spike, a bag of Sterile Water for Injection and the SmartPak<span class="Sup">Â®</span> Pharmacy Bulk Package.Â  Using aseptic technique </p>
<p>a.Â Â Â Â  Open the package containing the transfer tubing set.</p>
<p>b.Â Â Â Â  Attach the individually packaged spike to the unspiked end of the transfer tubing set.</p>
<p>c.Â Â Â Â  Insert this [removable] spike into the spike port of the bag of Sterile Water for Injection [diluent]. </p>
<p>d.Â Â Â Â  Attach the non removable spike of the same tubing set into the Transfer Port of the SmartPak<span class="Sup">Â® </span>Pharmacy Bulk Package.</p>
<p>2.Â Â Â Â Â Â Â Â  Transfer the appropriate amount of Sterile Water for Injection into the SmartPak<span class="Sup">Â®</span> Pharmacy Bulk Package by pressing the reverse button of the pump.</p>
<p>3.Â Â Â Â Â Â Â Â  After completing the transfer of the appropriate amount of Sterile Water for Injection, aseptically remove the spike from the bag of Sterile Water for Injection, and disconnect the spike from this end of the tubing set.Â  </p>
<p>4.Â Â Â Â Â Â Â Â  Aseptically replace this spike with a transfer needle, and insert this needle into the Reconstitution Port of the SmartPak<span class="Sup">Â®</span> Pharmacy Bulk Package.</p>
<p>5.Â Â Â Â Â Â Â Â  Using the pump, circulate the reconstituted drug through the tubing set and SmartPak<span class="Sup">Â®</span> Pharmacy Bulk Package to thoroughly mix (about 15 minutes for the 75 gram container and 25 minutes for the 225 gram container).</p>
<p>6.Â Â Â Â Â Â Â Â  After solution is complete, aseptically remove the transfer needle from the Reconstitution Port of the SmartPak<span class="Sup">Â®</span> Pharmacy Bulk Package, and replace it with a syringe filling adaptor.</p>
<p>7.Â Â Â Â Â Â Â Â  Hang the bag from the eyelets support.Â  Using a pump, aseptically transfer the reconstituted solution from the SmartPak<span class="Sup">Â®</span> Pharmacy Bulk Package, through the tubing set in the Transfer Port, into syringes via the syringe filling adaptor.</p>
<p>It should be noted that the spike placed into the SmartPak<span class="Sup">Â®</span> Pharmacy Bulk Package in Step1.d. is NEVER removed during this procedure and that the Reconstitution Port is self-sealing.Â Â Â  </p>
<p>Solutions should be allowed to stand after dissolution to allow any foaming to dissipate in order to permit visual inspection for completed solubilization.Â  <span class="Bold">CAUTION:Â  TO AVOID POSSIBLE LEAKAGE CAUSED BY THE HEAVY WEIGHT OF THE ADDED WATER, DO NOT SHAKE VIGOROUSLY OR PULL STRONGLY ON THE BAG.</span></p>
<p><span class="Bold">Dispensing Reconstituted Cefuroxime/Instructions for Filling Empty Syringes</span>:Â  Unscrew the clear threaded cap from the transfer (larger) port and discard it.Â  Using this transfer port, fill sterile empty syringes, using a new transfer device.Â  Syringes may be filled using aseptic technique following the usual practice of the individual institution.Â  Such practices may range from the use of a three-way stop cock to use of a calibrated peristaltic pump.Â  If reconstituted to 95 mg/mL:Â  dispense 8 mL for 750 mg or 16 mL for 1.5 grams.Â  If reconstituted to 100 mg/mL: dispense 7.5 mL for 750 mg or 15 mL for 1.5 grams.Â  For pediatric dosages, see <span class="Bold"><a href="#LINK_680d0363-0ee8-4b09-afd8-7de1fb9473a9">Pediatric Patients Above 3 Months of Age</a>.</span></p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_df5c06cb-0def-4c9f-ad24-6aaafd0f8f4f"></a><a name="section-10.3"></a><p></p>
<h2></h2>
<div class="Figure"><img alt="This is an impage of the proper procedure for reconstitiution and dispensing of the pharmacy bulk package." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=98ea197c-b3ff-47bc-8d0f-fce91b539959&amp;name=cefuroxime-2.jpg"></div>
<p class="First"><span class="Bold"><span class="Underline">RECONSTITUTION PHASE</span></span></p>
<p><span class="Bold">1.Â Â  </span><span class="Bold">Remove translucent reconstitution port cap by pulling</span></p>
<p><span class="Bold">2.Â Â  </span><span class="Bold">Insert new transfer device for reconstitution</span></p>
<p><span class="Bold">3.Â Â  </span><span class="Bold">Add appropriate volume of Sterile Water for Injection</span></p>
<p><span class="Bold">4.Â Â  </span><span class="Bold">Disconnect injection transfer device</span></p>
<p><span class="Bold">5.Â Â  </span><span class="Bold">See text of Package Insert for further details</span></p>
<p><span class="Bold"><span class="Underline">MIXING PHASE</span></span></p>
<p><span class="Bold">1.Â Â  </span><span class="Bold">Mix gently: either recirculate via a tubing loop or by picking up the bag and gently moving it from side to side until dissolution is completed (15 to 25 minutes) and foam, if any, dissipates</span></p>
<p><span class="Bold">2.Â Â  </span><span class="Bold">Check for particulate matter, leaks and discoloration (dark yellow or brown)</span></p>
<p><span class="Bold">3.Â Â  </span><span class="Bold">If any of the above are found, discard bag immediately</span></p>
<p><span class="Bold">4.Â Â  </span><span class="Bold">If satisfactory, hang bag, using the eyelets</span></p>
<p><span class="Bold">5.Â Â  See text of Package Insert for further details</span></p>
<p><span class="Bold"><span class="Bold"><span class="Underline">DISPENSING PHASE</span></span></span></p>
<p><span class="Bold">1.Â Â  </span><span class="Bold">Unscrew clear transferÂ  port cap</span></p>
<p><span class="Bold">2.Â Â  </span><span class="Bold">Insert new transfer device</span></p>
<p><span class="Bold">3.Â Â  </span><span class="Bold">Transfer dose into sterile empty syringe</span></p>
<p><span class="Bold">4.Â Â  </span><span class="Bold">Properly label syringes</span></p>
<p><span class="Bold">5.Â Â  </span><span class="Bold">See text of Package Insert for further details</span></p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_1ff8a2d7-3728-48b1-9ee8-4a6623751fe5"></a><a name="section-10.4"></a><p></p>
<h2><span class="Bold">Administration </span></h2>
<p class="First"><span class="Bold">BEFORE ADMINISTRATION, THIS PHARMACY BULK PACKAGE REQUIRES RECONSTITUTION TO A CONCENTRATION OF 95 mg/mL OR </span><span class="Bold">100 mg/mL AND TRANSFER INTO STERILE SYRINGES.</span></p>
<p>Cefuroxime for Injection, USP, SmartPak<span class="Sup">Â® </span>Pharmacy Bulk Packages are for intravenous use only following reconstitution and transfer into syringes. </p>
<p><span class="Bold"><span class="Italics">Intravenous Administration</span></span>:Â  The intravenous route may be preferable for patients with bacterial <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">septicemia</span> or other severe or life-threatening <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> or for patients who may be poor risks because of lowered resistance, particularly if <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> is present or impending.</p>
<p><span class="Bold"><span class="Italics">For direct intermittent intravenous administration</span></span>, slowly inject the solution into a vein over a period of 3 to 5 minutes or give it through the tubing system by which the patient is also receiving other intravenous solutions. </p>
<p><span class="Bold"><span class="Italics">For intermittent intravenous infusion with a Y-type administration set,</span></span> dosing can be accomplished through the tubing system by which the patient may be receiving other intravenous solutions.Â  However, during infusion of the solutions containing cefuroxime, it is advisable to temporarily discontinue administration of any other solutions at the same site.Â  </p>
<p>Solutions of cefuroxime, like those of most beta-lactam antibiotics, should not be added to solutions of aminoglycoside antibiotics because of potential interaction.Â  However, if concurrent therapy with cefuroxime and an aminoglycoside is indicated, each of these antibiotics can be administered separately to the same patient.</p>
<p>Stability of Filled SyringesÂ Â  </p>
<p>In those situations in which the drug has been reconstituted with water and transferred to empty syringes, but not immediately administered to the patient, the syringes may be stored under the following conditions:</p>
<ul class="Disk">
<li>24 hours at room temperature </li>
<li>7 days under refrigeration, 2Âº to 8ÂºC (36Âº to 46ÂºF), if immediately refrigerated after transfer.</li>
<li>12 weeks at â€“20Â° C, if immediately frozen after transfer.Â Â  </li>
</ul>
<p><span class="Bold"><span class="Bold">THAW FROZEN SYRINGES CONTAINING CEFUROXIME AT ROOM TEMPERATURE OR UNDER REFRIGERATION.Â  DO NOT FORCE THAW BY IMMERSION IN WATER BATHS OR BY MICROWAVE IRRADIATION.Â  IF, AFTER VISUAL INSPECTION, THE SOLUTION IS CLOUDY, CONTAINS PARTICULATE MATTER OR LEAKS ARE DETECTED, DISCARD THE SYRINGE AS <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">STERILITY</span> MAY BE IMPAIRED. DO NOT REFREEZE THAWED SYRINGES.Â  </span></span></p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_0a80e373-1e48-48dc-b3d2-8e3ccc33522a"></a><a name="section-11"></a><p></p>
<h1><span class="Bold">HOW SUPPLIED</span></h1>
<p class="First">Cefuroxime for Injection in the dry state should be stored between 15Â° to 30Â°C (59Â° to 86Â°F) and protected from light.Â  [See USP Controlled Room Temperature].Â Â  Cefuroxime is a dry, white to yellow powder.</p>
<p>Cefuroxime for Injection, USP, is available in the following SmartPak<span class="Sup">Â® </span>Pharmacy Bulk Packages:</p>
<p><span class="Bold">75 gram</span>* (1 Pharmacy Bulk Package), Product No. 2075 NDC 66288-2075-1</p>
<p><span class="Bold">225 gram</span> ** (1 Pharmacy Bulk Package), Product No. 2225 NDC 66288-2225-1</p>
<p>* Each 75 gram Pharmacy Bulk Package contains sterile cefuroxime sodium equivalent to 75 grams of cefuroxime</p>
<p>** Each 225 gram Pharmacy Bulk Package contains sterile cefuroxime sodium equivalent to 225 grams of cefuroxime</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="LINK_df360b16-9114-460c-8d4a-f503005dd0f9"></a><a name="section-12"></a><p></p>
<h1>REFERENCES</h1>
<p class="First">1. National Committee for Clinical Laboratory Standards. <span class="Italics">Performance Standards for </span><span class="Italics">Antimicrobial Susceptibility Testing. </span>Third Informational Supplement. NCCLS Document M100-S3, Vol. 11, No. 17. Villanova, Pa: NCCLS; 1991.</p>
<p>2. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. <span class="Italics">Nephron.Â  </span>1976;16:31-41.</p>
<p>Literature issued January 2010Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â C2075cÂ  </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_3f1ca9f7-5909-466b-80c1-ec130426b789"></a><a name="section-13"></a><p></p>
<h1></h1>
<p class="First">Manufactured for </p>
<p>SAMSON<br>MEDICAL TECHNOLOGIES L.L.C.<br>Cherry Hill, NJ 08003</p>
<p>by</p>
<p>ACS Dobfar S.p.A.<br>20067 Tribiano (Milano) Italy</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_c074b827-0a46-454d-b383-358a6a4cbd56"></a><a name="section-14"></a><p></p>
<h1><span class="Bold">PRINCIPAL DISPLAY PANEL</span></h1>
<div class="Figure"><img alt="This is an image of cefuoxime 75 grams label." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=98ea197c-b3ff-47bc-8d0f-fce91b539959&amp;name=cefuroxime-3.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_ff75359a-4a4d-44f6-a91f-a9440ca32658"></a><a name="section-15"></a><p></p>
<h1><span class="Bold">PRINCIPAL DISPLAY PANEL</span></h1>
<div class="Figure"><img alt="This is an imaage of the cefuroxime label 225 grams." src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=98ea197c-b3ff-47bc-8d0f-fce91b539959&amp;name=cefuroxime-4.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CEFUROXIME SODIUMÂ 		
					</strong><br><span class="contentTableReg">cefuroxime sodium injection, powder, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:66288-2075</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CEFUROXIME SODIUM</strong> (CEFUROXIME) </td>
<td class="formItem">CEFUROXIME SODIUM</td>
<td class="formItem">75Â g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (white to yellow) </td>
<td class="formLabel">Score</td>
<td class="formItem">Â Â Â Â </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:66288-2075-1</td>
<td class="formItem">1  in 1 BAG</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA065251</td>
<td class="formItem">02/01/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CEFUROXIME SODIUMÂ 		
					</strong><br><span class="contentTableReg">cefuroxime sodium injection, powder, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:66288-2225</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CEFUROXIME SODIUM</strong> (CEFUROXIME) </td>
<td class="formItem">CEFUROXIME SODIUM</td>
<td class="formItem">225Â g</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (white to yellow) </td>
<td class="formLabel">Score</td>
<td class="formItem">Â Â Â Â </td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem"></td>
<td class="formLabel">Size</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:66288-2225-1</td>
<td class="formItem">1  in 1 BAG</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA065251</td>
<td class="formItem">02/01/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Samson Medical Technologies, L.L.C.
							(102837429)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ACS Dobfar S.p.A.,</td>
<td class="formItem"></td>
<td class="formItem">429243025</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>055f264a-ca6d-4866-81c2-6b2898460880</div>
<div>Set id: 98ea197c-b3ff-47bc-8d0f-fce91b539959</div>
<div>Version: 3</div>
<div>Effective Time: 20100208</div>
</div>
</div>Â <div class="DistributorName">Samson Medical Technologies, L.L.C.</div></p>
</body></html>
